The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection
For patients with high-risk HCC, postoperative adjuvant therapy employing tislelizumab for a duration exceeding 6 months may represent a viable strategy for reducing the risk of tumor recurrence.
Authors
- Shuchang Chen (ORCID: https://orcid.org/0000-0001-8374-2672)
- Jia‐Yong Su (ORCID: https://orcid.org/0000-0002-0960-5394)
- Ze Su (ORCID: https://orcid.org/0009-0000-1360-0783)
- Jian‐Hong Zhong (ORCID: https://orcid.org/0000-0002-1494-6396)
- Ning Peng (ORCID: https://orcid.org/0000-0003-4213-1159)
- Linfeng Mao (ORCID: https://orcid.org/0000-0001-8113-1253)
- Yong-Heng Zhou
- Wenfeng Li (ORCID: https://orcid.org/0000-0002-3250-3062)
- Fuquan Yang (ORCID: https://orcid.org/0000-0002-2841-5342)
- Shaoping Liu
- Le Li (ORCID: https://orcid.org/0009-0005-7015-5512)
- Jun‐Jie Ou (ORCID: https://orcid.org/0009-0003-2700-1118)
Institutions
- Guangxi Medical University (CN)
- Guigang City People's Hospital (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- First People's Hospital of Nanning (CN)
- Tumor Hospital of Guangxi Medical University (CN)
- Yulin University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1593153
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- National Natural Science Foundation of China
- Guangxi Medical University
- Guangxi Key Research and Development Program